Product Description
Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a616007.html)
Mechanisms of Action: ALK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Panama, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 48
Highest Development Phases
Phase 3: Large Cell Carcinoma|Large-Cell Anaplastic Lymphoma|Lymphoma|Lymphoproliferative Disorders|Neuroblastoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma
Phase 2: Abnormalities, Multiple|Anal Cancer|Bladder Cancer|Brain Cancer|Breast Cancer|Central Nervous System Cancer|Clear Cell Sarcoma|Glioblastoma|Hodgkin Lymphoma|Intestinal Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Primary Central Nervous System Lymphoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Vision, Low
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2021220007 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2035-04-14 |
|
| BO42777 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2033-09-01 |
|
| 2021-004149-19 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2033-08-07 |
|
| GO42286 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2033-06-30 |